Since insulin resistance plays a vital role in the pathophysiology of T2DM, insulin sensitizer agents occupy the first place in the T2DM pharmacopeia, and new agents with this potential effect have been extensively investigated. Here, INS is linked to type 2 diabetes mellitus.